Amgen (NASDAQ:AMGN – Get Free Report) had its target price boosted by The Goldman Sachs Group from $403.00 to $415.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s target price suggests a potential upside of 20.06% from the stock’s current price.
Several other analysts have also commented on AMGN. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 15th. Guggenheim boosted their target price on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Daiwa Capital Markets lifted their price objective on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Cantor Fitzgerald upped their target price on shares of Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $344.83.
Check Out Our Latest Report on AMGN
Amgen Stock Performance
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company earned $5.31 EPS. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts forecast that Amgen will post 20.62 earnings per share for the current year.
Insider Buying and Selling
In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Insiders own 0.69% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of AMGN. Asahi Life Asset Management CO. LTD. lifted its position in shares of Amgen by 2.7% in the fourth quarter. Asahi Life Asset Management CO. LTD. now owns 10,462 shares of the medical research company’s stock valued at $3,424,000 after acquiring an additional 276 shares in the last quarter. Drive Wealth Management LLC boosted its position in shares of Amgen by 40.6% during the fourth quarter. Drive Wealth Management LLC now owns 1,405 shares of the medical research company’s stock worth $460,000 after acquiring an additional 406 shares during the last quarter. ABN AMRO Bank N.V. grew its stake in Amgen by 56.1% during the fourth quarter. ABN AMRO Bank N.V. now owns 4,978 shares of the medical research company’s stock valued at $1,626,000 after acquiring an additional 1,788 shares in the last quarter. Strait & Sound Wealth Management LLC increased its holdings in Amgen by 4.9% in the 4th quarter. Strait & Sound Wealth Management LLC now owns 5,309 shares of the medical research company’s stock valued at $1,738,000 after acquiring an additional 246 shares during the last quarter. Finally, Income Insurance Ltd purchased a new stake in Amgen in the 4th quarter worth $526,000. 76.50% of the stock is owned by hedge funds and other institutional investors.
More Amgen News
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Q4 results beat Street estimates — Amgen reported $5.29 EPS on $9.87B revenue, ahead of expectations, and cited volume growth and a lower tax rate as drivers of the upside; these beats support the company’s outlook and were the main near-term bullish catalyst. Amgen quarterly results beat Street estimates on higher sales, lower tax rate (Reuters)
- Positive Sentiment: Analyst upgrade/price-target lift — Leerink Partners raised its price target to $355 and kept an outperform view, signaling bullish conviction from some buy‑side analysts and providing upside to the stock. Leerink raises AMGN price target to $355 (Benzinga)
- Positive Sentiment: Pipeline and product momentum — Coverage notes highlight product-portfolio expansion and pipeline progress (new launches contributing to double‑digit revenue/EPS growth for 2025), which underpin management’s outlook. AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook (Yahoo)
- Neutral Sentiment: Mixed analyst views — Some publications note divergent analyst opinions on valuation and near‑term risks, producing a mixed consensus that can limit a stronger rally. Analysts’ Opinions Are Mixed on These Healthcare Stocks (Globe and Mail)
- Negative Sentiment: Regulatory and LOE concerns — Analysis flags regulatory tensions around Tavneos and the challenge of mitigating loss‑of‑exclusivity (LOE) impacts, which increase execution risk and could pressure future growth if approvals or launches are delayed. Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (Seeking Alpha)
- Negative Sentiment: Analyst caution on legacy erosion and execution — Some analysts (Citi/TipRanks) maintained or reiterated hold ratings, citing legacy-product erosion and execution risks that justify a more cautious stance and likely contributed to the stock pulling back. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks (TipRanks)
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Further Reading
- Five stocks we like better than Amgen
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
